Current and emerging antiviral treatments for hepatitis C infection

被引：45

作者：

Doyle, Joseph S. ^{[1
,2
,3
]}

Aspinall, Esther ^{[7
]}

Liew, Danny ^{[4
]}

Thompson, Alexander J. ^{[5
,6
,8
,9
]}

Hellard, Margaret E. ^{[1
,2
,3
]}

机构：

[1] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic 3004, Australia

[2] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia

[3] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia

[4] Univ Melbourne, Dept Med RMH, Melbourne EpiCtr, Melbourne, Vic, Australia

[5] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[6] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[7] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland

[8] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[9] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 75卷 / 04期

基金：

英国医学研究理事会;

关键词：

antiviral therapy; direct acting antiviral; hepatitis C virus; polymerase inhibitors; protease inhibitors; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT-NAIVE PATIENTS; ALPHA-2A PLUS RIBAVIRIN; PROTEASE INHIBITOR; POLYMERASE INHIBITOR; PEGINTERFERON ALPHA-2A; VIRUS-INFECTION; VIRAL RESPONSE; HCV INFECTION; DRUG-USERS;

D O I：

10.1111/j.1365-2125.2012.04419.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Newly licensed direct acting antivirals for hepatitis C virus HCV are able to cure up to 75% of patients chronically infected with genotype-1 infection, which is the predominant HCV strain in Europe and North America. Emerging antiviral therapies promise further increases in virological response, as well as improved tolerability, reduced duration of therapy, and will potentially eliminate the need for interferon use. This review highlights the main therapeutic agents used in current standard of care, including telaprevir and boceprevir. It goes on to evaluate the mechanisms of emerging drugs, their stage of development and response rates seen in research to date. Finally, it projects into the not too distant future to consider treatment strategies involving combinations of agents and interferon-free therapies, and in which patients they might prove most successful.

引用

页码：931 / 943

页数：13

共 90 条

[1] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[2] Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects [J].

Bartels, Doug J. ;

Zhou, Yi ;

Zhang, Eileen Z. ;

Marcial, Michelle ;

Byrn, Randal A. ;

Pfeiffer, Thomas ;

Tigges, Ann M. ;

Adiwijaya, Bambang S. ;

Lin, Chao ;

Kwong, Ann D. ;

Kieffer, Tara L. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (06) :800-807

[3] A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C: ViSER1 Results [J].

Benhamou, Yves ;

Afdhal, Nezam H. ;

Nelson, David R. ;

Shiffman, Mitchell L. ;

Halliman, Deanine G. ;

Heise, Jamie ;

Chun, Eric ;

Pockros, Paul J. .

HEPATOLOGY, 2009, 50 (03) :717-726

[4] Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy [J].

Berg, T ;

Sarrazin, C ;

Herrmann, E ;

Hinrichsen, H ;

Gerlach, T ;

Zachoval, R ;

Wiedenmann, B ;

Hopf, U ;

Zeuzem, S .

HEPATOLOGY, 2003, 37 (03) :600-609

[5] Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV [J].

Bergmann, J. F. ;

de Bruijne, J. ;

Hotho, D. M. ;

de Knegt, R. J. ;

Boonstra, A. ;

Weegink, C. J. ;

van Vliet, A. A. ;

van de Wetering, J. ;

Fletcher, S. P. ;

Bauman, L. A. ;

Rahimy, M. ;

Appleman, J. R. ;

Freddo, J. L. ;

Janssen, H. L. A. ;

Reesink, H. W. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (04) :443-453

[6] Future treatment of patients with HCV cirrhosis [J].

Bourliere, Marc ;

Khaloun, Asma ;

Wartelle-Bladou, Claire ;

Oules, Valerie ;

Portal, Isabelle ;

Benali, Souad ;

Adhoute, Xavier ;

Castellani, Paul .

LIVER INTERNATIONAL, 2012, 32 :113-119

[7] BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION [J].

Bronowicki, J. -P. ;

Pol, S. ;

Thuluvath, P. J. ;

Larrey, D. ;

Martorell, C. T. ;

Rustgi, V. K. ;

Morris, D. W. ;

Younes, Z. ;

Fried, M. W. ;

Bourliere, M. ;

Hezode, C. ;

Massoud, O. ;

Abrams, G. A. ;

Ratziu, V. ;

Thiry, A. ;

Llamoso, C. ;

Hughes, E. A. ;

Hindes, R. G. .

JOURNAL OF HEPATOLOGY, 2011, 54 :S472-S472

[8] Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis [J].

Camma, Calogero ;

Cabibbo, Giuseppe ;

Bronte, Fabrizio ;

Enea, Marco ;

Licata, Anna ;

Attanasio, Massimo ;

Andriulli, Angelo ;

Craxi, Antonio .

JOURNAL OF HEPATOLOGY, 2009, 51 (04) :675-681

[9] Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders [J].

Chayama, Kazuaki ;

Takahashi, Shoichi ;

Toyota, Joji ;

Karino, Yoshiyasu ;

Ikeda, Kenji ;

Ishikawa, Hiroki ;

Watanabe, Hideaki ;

McPhee, Fiona ;

Hughes, Eric ;

Kumada, Hiromitsu .

HEPATOLOGY, 2012, 55 (03) :742-748

[10] A Watershed Moment in the Treatment of Hepatitis C [J].

Chung, Raymond T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (03) :273-275

← 1 2 3 4 5 6 7 8 9 →